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Um rearranjo de Curtius, utilizando adutos de Morita-Baylis-Hillman como substrato, foi 
realizado em uma sequência que permitiu a síntese de várias hidroxi-cetonas (aciloínas) com 
uma grande diversidade estrutural e com bons rendimentos globais. Por sua vez, essas aciloínas 
foram transformadas em 1,2-amino-alcoóis de configuração relativa anti, através de uma etapa 
de aminação redutiva altamente diastereosseletiva. A utilidade sintética dessas abordagens foi 
demonstrada através das sínteses totais da (±)-bupropiona, fármaco utilizado no tratamento na 
síndrome de abstinência de fumantes e da (±)-espisulosina, um potente agente anti-tumoral isolado 
inicialmente de uma fonte marinha.
Using Morita-Baylis-Hillman adducts as substrates, the Curtius rearrangement was performed 
in a sequence that allowed the synthesis of several hydroxy-ketones (acyloins) with great structural 
diversity and in good overall yields. These acyloins in turn were easily transformed into 1,2-anti 
aminoalcohols through a highly diastereoselective reductive amination step. The synthetic utility 
of these approaches was exemplified by performing the syntheses of (±)-bupropion, a drug used 
to treat the abstinence syndrome of smoker and (±)-spisulosine, a potent anti-tumoral compound 
originally isolated from a marine source.
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Introduction
The formation of new C–N bonds by incorporation 
of a nitrogen atom into a molecule is a fundamental 
transformation in organic chemistry, since it allows 
accessing many valuable compounds.1 Basically, this can 
be achieved by nucleophilic substitution reactions or by 
electrophilic amination reactions.2
A C–N bond can also be built through rearrangement 
reactions. For instance, Lossen,3 Beckman,4 Schmidt5 and 
Curtius6 rearrangements are processes which allow the 
efficient formation of a new C–N bond from carbonyl 
containing derivative compounds.
The Curtius rearrangement is a thermal decomposition 
of a carbonyl azide leading to an isocyanate. This 
stereospecific rearrangement provides carbamates or amines 
in good overall yields and selectivities. Unfortunately, this 
rearrangement has the drawback that low molar mass acyl 
azides present an explosion hazard.7 This safety issue 
has limited the industrial use of this transformation until 
recently, when Am Ende et al.8 reported a new experimental 
protocol, which enabled the use of this reaction under safer 
conditions even when conducted on a large scale. This and 
other protocols have revived interest in this rearrangement, 
particularly for industrial purposes.9
Regarding the potential of this rearrangement, our group 
has recently reported the preparation of some carbamates 
from Morita-Baylis-Hillman (MBH) adducts.10 Curtius 
rearrangement would be the best way to achieve our target, 
since the carboxyl group in this structure is needed to 
perform this rearrangement. Thus, when an acid derived 
from a MBH adduct was treated with sodium azide, 
heated at reflux and treated subsequently with t-butanol, 
the corresponding ene-carbamate was formed in good 
overall yield. However, in some examples it was observed 
the occurrence of a byproduct (ca. 12-15%) which was 
characterized as being an acyloin (Scheme 1).
The acyloin formation was easily explained by the 
presence of water (tiny amount) in the t-BuOH used 
to transform the intermediate ene-isocyanate into the 
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corresponding ene-carbamate. This undesirable side 
reaction caught our attention, since a-hydroxyketones 
(acyloins) are structural motifs present in several 
biologically active compounds, in which the activity is 
closely associated with the presence of this structural 
pattern. Due to the synthetic and biological relevance 
of acyloins, several synthetic approaches have already 
been developed in order to prepare them. Conventionally, 
a-hydroxy ketones are prepared by the acyloin condensation 
reaction,11 oxidation of enolates or double bonds,12 or 
reduction of a-diketones or esters.13 Recently, a method 
based on ketohydroxylation of alkenes was developed 
to give acyloins.14 Alternatively, radical oxidation of a 
1,3-dicarbonyl compound with cerium salts could also 
be used for the preparation of acyloins.15 Most recently, a 
skeletal rearrangement of symmetrically a,a-disubstituted 
a-amino aldehyde has been reported as a new strategy for 
preparing acyloins.16
Beyond its biological importance, a-hydroxyketones 
are also an interesting synthetic platform that allows further 
chemical transformations. For instance, a a-hydroxyketone 
can be easily transformed into a a-aminoketone. This 
structural pattern is present in some commercial drugs, such 
as bupropion [(±)-a-t-butylamino-3-chloropropiophenone] 
(1, Figure 1), a potent synthetic inhibitor of dopamine 
reuptake with subtle noradrenergic reuptake.17 Bupropion 
is an atypical antidepressant, which has been licensed by 
FDA to treat the abstinence syndrome of smokers.18
Vicinal aminoalcohols (or 1,2-aminoalcohols) are 
structural units that currently occur in several biologically 
active compounds. They are also part of several chiral 
catalysts and new materials.
The biological and synthetic importances of this structural 
motif have stimulated the development of several methods 
to synthesize it, both in racemic and enantiomerically 
pure forms.19 Classically, syn-1,2-aminoalcohols can be 
prepared in their racemic or asymmetric versions using the 
aminohydroxylation strategy developed by Sharpless et al.20 
Another efficient way to prepare vicinal aminoalcohols 
is by the opening of an epoxide ring with a suitable 
nitrogen source, such as amines or azide ions, to provide 
aminoalcohols or azidoalcohols, respectively.21,22
By using simple chemical  transformations, 
a-hydroxyketones (acyloins) can also be used as substrates 
for the stereoselective preparation of 1,2-aminoalcohols.23
Spisulosine (2, Figure 1) is a sphingoid-type base 
which presents a long unsaturated alkyl chain (C15) and 
a 1,2-aminoalcohol motif in an anti relationship.24 This 
compound was isolated from extracts obtained from the 
clam Spisula polynyma and exhibits a promising activity 
against prostate cancer.25
In a research program directed towards the total 
synthesis of drugs from Morita-Baylis-Hillman adducts,26 
we describe herein the synthesis of a-hydroxyketones 
and their diastereoselective transformations into 
anti-1,2-aminoalcohols. To exemplify the synthetic utility 
of this approach, we also describe the syntheses of the drugs 
(+/-)-bupropion and (+/-)-spisulosine.
Results and Discussion
The present work began by preparing the MBH 
adducts, according to a procedure previously developed in 
our laboratory.27 The strategy provides the corresponding 
adducts in good to high yields. The results are summarized 
in Table 1.
Initially, the Curtius rearrangement without protection 
































Figure 1. Molecular structures of bupropion and spisulosine.
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work. So, adduct 3 was hydrolysed in the presence of LiOH 
in an acetonitrile:H2O (1:1) mixture to give a hydroxyacid 
in almost quantitative yield (> 98%). When this acid was 
treated with ethyl chloroformate, extensive degradation of 
our starting material was observed by TLC analysis.
In an attempt to circumvent this issue, the secondary 
hydroxyl group of the MBH adducts was protected, before 
ester hydrolysis. Thus, adducts 3-12 were treated with 
TBSCl or TBSOTf in DMF or dichloromethane, in the 
presence of imidazole or triethylamine, respectively. The 
silylated adducts (13-22) were obtained in good to excellent 
yields. Soon after, ester hydrolysis was carried out with 
LiOH, in an acetonitrile:H2O mixture at 60 °C to produce 
acids 23-32 in excellent yields. The results of these steps 
are summarized in Table 2.
The Curtius rearrangement was initiated using 
diphenylphosphoryl azide (DPPA).28 This reagent is 
supposed to react with a carboxylic acid to provide an 
isocyanate in a single step. A solution of silyl-acid 23 in 
toluene was therefore treated with DPPA at reflux for 20 h. 
Unfortunately, it was unable to isolate any isocyanate. 
Instead, a complete destruction of the silylated acid was 
observed.
Because of this result, it was decided to perform the 
Curtius rearrangement by using a classical experimental 
protocol. Thus, an acetone solution of silylated acids 
was treated with ethyl chloroformate in the presence of 
triethylamine at 0 °C for 5 min. After that, sodium azide 
was added to the reaction mixture and this mixture was 
vigorously stirred for 2 h. The crude products were refluxed 
in dry toluene for 2 h to give the corresponding isocyanates, 
which finally were refluxed in water to furnish a set of 
acyloins in good overall yield (ranging from 35 to 50% for 
3 steps). The results are summarized in Table 3.
Acyloins were obtained in good overall yield in three 
steps from Morita-Baylis-Hillman adducts. The strategy 
is simple and requires no special conditions such as low 
temperature, dry solvents or special catalysts. Moreover, it 
uses reagents which are routinely found in organic synthesis 
laboratories.
Table 1. Morita-Baylis-Hillman adducts
Entry Aldehyde MBH adduct, yield / %a
1 2-nitrobenzaldehyde 3, 92
2 3-chlorobenzaldehyde 4, 89
3 benzaldehyde 5, 75
4 4-methoxybenzaldehyde 6, 77
5 3,4,5-trimethoxybenzaldehyde 7, 60
6 thiophenecarboxaldehyde 8, 90
7 2-fluorobenzaldehyde 9, 95
8 propanaldehyde 10, 80
9 hexanaldehydeb 11, 76
10 hexadecanaldehydec 12, 60
aYields refer to isolated and purified products; bMBH reaction was 
performed with excess of methyl acrylate in the presence of [bmim]PF6 
at 0 °C; cprepared by oxidation of commercial hexadecanol with PCC in 
refluxing dichloromethane in 95% yield.






















Entry MBH adducts Silylated adducts, yield / %a Silylated acids, yield / %a
1 3 13, 97 23, 97
2 4 14, 99 24, 99
3 5 15, 99 25, 99
4 6 16, 99 26, 98
5 7 17, 99 27, 99
6 8 18, 90 28, 99
7 9 19, 85 29, 99
8 10 20, 85 30, 99
9 11 21, 99 31, 98
10 12 22, 70 32, 99b
aYields refer to isolated and purified products; bmethanol used as solvent and NaOH used as base instead of LiOH.
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The bifunctional identity (one eletrophilic group and 
another nucleophilic) makes acyloins an important building 
block in organic synthesis. They can be converted into 
several different functional groups, such as alcohols, diols, 
epoxides, amines, hydroxylamines and haloketones. This 
synthetic versatility explains the frequent use of acyloins 
as building blocks for the synthesis of pharmaceutical 
compounds.29
A ketone carbonyl group can be promptly transformed 
into an amine by a reductive amination reaction. 
Applications of this reaction are widespread in the 
pharmaceutical, agrochemical and chemical industries, and 
in materials science and biotechnology.30-32
Recently, Cabral et al.33 have developed a simple 
method to perform a reductive amination, based on in situ 
formation of an iminium, followed by reduction with 
LiBH4. Thus, this was viewed in the present work as an 
attractive opportunity to test this method to prepare vicinal 
aminoalcohols from our acyloins.
A methanol solution of 35 was treated with LiBH4 in the 
presence of an excess of benzylamine (3 equiv.) at −72 °C 
to give aminoalcohol 46 in 83% yield and excellent 1,2-anti 
diastereoselectivity (97:3 d.r., anti:syn). This simple sequence 
has allowed the development of a highly diastereoselective 
synthesis of several different aminoalcohols in good yields. 
The results are summarized in Table 4.
For all cases examined, the vicinal aminoalcohols 
were obtained in good yields and with excellent 
diastereoselectivities. To confirm the 1,2-anti relative 
stereochemistry, the silyl protecting group of aminoalcohol 
44 was removed by treatment with TBAF. The unprotected 
vicinal aminoalcohol 55 was reacted with triphosgene to 





i) ClCO2Et, acetone, 5 oC, 5 min
ii) NaN3, r.t., 2 h
iii) toluene, reflux, 2 h






Entry R Acyloin Yield / %a,b
1 2-nitrophenyl 33 46
2 3-chlorophenyl 34 45
3 phenyl 35 50
4 4-methoxyphenyl 36 48
5 3,4,5-trimethoxyphenyl 37 42
6 thienyl 38 44
7 2-fluorophenyl 39 41
8 ethyl 40 46
9 hexyl 41 42
10 hexadecanyl 42 40
aYields refer to isolated and purified products; boverall yield (3 steps 
from silyl esters).













Entry Acyloin (R) Amine (R1) Yield / %a d.r.b
1 34, 3-chlorophenyl phenethyl 43, 79 96:4
2 34, 3-chlorophenyl benzyl 44, 77 92:8
3 35, phenyl phenethyl 45, 85 > 95:5
4 35, phenyl benzyl 46, 83 97:3
5 35, phenyl allyl 47, 82 98:2
6 35, phenyl cyclohexyl 48, 80 93:7
7 37, 3,4,5-trimethoxyphenyl phenethyl 49, 81 > 95:5
8 37, 3,4,5-trimethoxyphenyl allyl 50, 80 87:13
9 38, thienyl phenethyl 51, 82 91:9
10 39, 2-fluorophenyl phenethyl 52, 78 > 95:5
11 40, ethyl phenethyl 53, 73 > 95:5
12 40, ethyl decyl 54, 71 > 95:5
aYields refer to isolated and purified products; bdiastereoisomeric ratio was determined by analysis of the 1H NMR spectra of the crude reaction mixture. 
The carbinolic proton shows a doublet with a coupling constant of 5 Hz for the anti relationship, while the syn product shows a coupling constant of 8.2 Hz.
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afford oxazolidinone 56, in 70% yield (Scheme 2). The 
coupling constant between hydrogens Ha and Hb was found 
to be 8.2 Hz, which it is in agreement with typical coupling 
constants for a cis relationship in oxazolidinones formed 
from a 1,2-anti aminoalcohol (Scheme 2).34
The presence of a bulky protecting group on the 
secondary hydroxyl group might play an important role in 
the iminium reduction step. Most likely the hydride attack 
occurs at the opposite side from the protecting group. To 
experimentally validate this hypothesis, silylated acyloin 
35 was treated with TBAF in methanol to provide acyloin 
57 in 80% yield. A methanol solution of 57 at −72 °C was 
treated with LiBH4 to afford aminoalcohol 58 in 70% yield 
and moderate diastereoselectivity (87:13 d.r.; anti:syn) 
(Scheme 3).
This result shows the effect of the silyl protecting 
group on the diastereoselectivity of the reduction step. 
Besides, the lithium atom could be complexed both with 
the nitrogen and the oxygen lone pairs (Figure 2). This 
arrangement allows the hydride to approach only from the 
less hindered side. The oxygen atom attached to the silicon 
of the TBS group has a low basicity, however it is still able 
to establish intramolecular hydrogen bonds in order to 
control stereoselectivities of reactions.35
The Curtius rearrangement carried out with MBH 
adducts has allowed the development of a new approach 
to prepare a-hydroxyketones, which have been used to 
prepare diastereoselective 1,2-anti vicinal aminoalcohols.
Searching to demonstrate the synthetic utility of these 
approaches, the total synthesis of two pharmacologically 
active compounds is now described. (±)-Bupropion 
(1, Figure 1) is an aminoketone acting on CNS.36 This 
compound is commmercialized in its racemic form, since 
it racemizes very quickly in the body when administered in 
its enantiomerically pure form. Our target compound could 
be prepared from acyloin 34 (Figure 3). A 1,2-carbonyl 
transposition reaction is required to provide 59, which can 
be converted uneventfully to (±)-1.37
A direct way to perform the required 1,2-carbonyl 
transposition was using the Lobry-de Bruyn-van Ekenstein 
transformation.38 This reaction, currently used in carbohydrate 
chemistry, is essentially an enolization of a sugar having a 
hydrogen at the a-carbon to the carbonyl group and proceeds 
via an enediol intermediate. Some acyloins rearrange with 
positions exchanged under the influence of base in this 
transformation. To test this alternative, the TBS group of 
acyloin 34 was removed by treatment with TBAF in methanol 
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Figure 3. Synthesis of (±)-bupropion from acyloin 34.
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75% yield. A methanol solution of this acyloin was reacted 
with a 30% solution of NaOH at room temperature. As a 
result, an extensive acyloin degradation was observed even 
at lower temperatures (−5 and −10 °C). We also tested the 
Voight amination (formation of ketoamine by treatment of 
an acyloin with P2O5 in the presence of a primary amine), 
however this reaction also failed.39
Due to these results, the synthetic approach towards the 
synthesis of bupropion was changed. As an alternative, the 
required transposition could be done in three steps. Thus, 
carbonyl reduction of the acyloin (±)-34 directly led to a 
monoprotected diol (±)-60 in almost quantitative yield. TBS 
removal was performed in the presence of TBAF to afford 
diol (±)-61 in 97% yield, as a mixture of diastereoisomers. 
Selective benzylic oxidation of (±)-61 with IBX in DMSO 
expectedly led to the 1,2-carbonyl transposition product 
(±)-59, as the sole product, in 85% yield (3 steps, 81% 
overall yield, Scheme 4).
Bupropion, in its racemic version, was obtained in 7 
steps from Morita-Baylis-Hillman 4, in 27% overall yield. 
The sequence is facile to execute and can be scaled-up 
without problems.
The synthetic methods described in this paper can be 
combined in order to synthesize spisulosine (2, Figure 1) 
as a racemate. This natural anti-tumoral compound can 
be prepared from acyloin 42, using a diastereoselective 
reductive amination step (Scheme 5).
The diastereoselective total synthesis of spisulosine was 
accomplished from acyloin (±)-42 using a very simple and 
direct sequence. Reductive amination of acyloin (±)-42 was 
performed with an excess of benzylamine to give vicinal 
aminoalcohol (±)-62, with high anti diastereoselectivity 
(> 95:5, anti:syn), in 68% yield (Scheme 6). To quickly 
finish the synthesis, it was only necessary to remove the 
protecting groups (TBS and benzyl). For thus, a solution 
of (±)-62 in methanol was acidified with some drops 
of concentrated HCl and the mixture was poured into 
a hydrogenating bottle containing 10% Pd on charcoal 
(10 mol%). To our surprise, after several hours at 60 psi, 
neither of the protecting groups was removed. Perhaps, 
the long carbon chain favoured the formation of mycelles, 
which could interact with the solid catalyst.
To solve this unexpected issue, a mixture of solvents for 
the hydrogenation reaction was used. Thus, a mixture of 
(±)-62 in dichloromethane:acetic acid (1.5:1) in the presence 
of 10% Pd/C at 60 psi and 50 °C was shaken for 20 h to 
furnish the debenzylated aminoalcohol (±)-63 in 87% yield. 
Finally, the TBS group of (±)-63 was removed by 
the treatment with concentrated HCl (0.1 mL) in a 
solution of dichoromethane:methanol (1:1; 1 mL) to give 
(±)-spisulosine (2) in 98% yield. All spectroscopic and 
physical data are identical to those described in literature 
for natural and synthetic spisulosine (Scheme 6).24,40
Spisulosine was synthetized in 7 steps from hexadecanal 
with an overall yield of 10%. The strategy is very simple 
and requires no special conditions such as low temperature 
or dry solvents. If the sequence begins with adduct 12 
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Scheme 4. Racemic total synthesis of bupropion from an acyloin.
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Scheme 5. Retrosynthesis of spisulosine (2).
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enantioselective synthesis of spisulosine. By using this 
strategy, spisulosine derivatives can also be synthesized 
using the sequence described herein.
Conclusions
In summary, the Curtius rearrangement coupled with 
Morita-Baylis-Hillman adducts as substrate has proven to 
be an alternative for the preparation of interesting building 
blocks for organic syntheses. This combination allowed 
the synthesis of a set of acyloins in good overall yields for 
three steps. Reductive amination of these acyloins gave 
vicinal aminoalcohols in good overall yields and with 
high diastereoselectivities, in favor of the 1,2-anti isomer. 
Moreover, we have demonstrated that these methods can 
be used in the synthesis of important pharmacologically 
active compounds. Thus, (±)-bupropion was prepared in 
7 steps from a MBH adduct, in 27% overall yield. Using 
this strategy we also showed a highly diastereoselective 
total synthesis of (±)-spisulosine which was accomplished 
in 7 steps from hexadecanal with an overall yield of 10%.
Experimental
General procedure
The 1H and 13C NMR spectra were recorded on a Bruker 
at 250 and 62.5 MHz, respectively, or on an Inova instrument 
at 500 and 125 MHz, respectively. High resolution mass 
(HRMS) spectra were recorded using a Q-TOF Micromass 
equipment (Waters, UK). Manipulations and reactions were 
not performed under dry atmospheres or employing dry 
solvents, unless otherwise specified. In those cases CH2Cl2, 
DMF and triethylamine were dried over CaH2 and distilled. 
Purification and separations by column chromatography 
were performed on silica gel, using normal or flash 
chromatography. Thin layer chromatography (TLC) was 
detected by spraying with 5% ethanolic phosphomolybdic 
acid and heating. All the Morita-Baylis-Hillman reactions 
were sonicated in an ultrasonic cleaner (81 W, 40 MHz).
General procedure for the synthesis of the Morita-Baylis-
Hillman adducts
A mixture of aldehyde (3-10 mmol), methyl acrylate 
(excess, ca. 5 equiv.) and DABCO (0.65 equiv.) was 
sonicated in an ultrasound bath at 30 °C. Reaction evolution 
was followed by TLC analysis. For the preparation of 
the MBH adducts 10 and 12 the reaction was carried 
out using methyl acrylate (10 equiv.), ionic liquid 
([bmim]BF4; 5 drops) as an additive, at 50 
oC with stirring. 
The excess of methyl acrylate was removed under vaccum. 
The crude residue was diluted in ethyl acetate (25 mL). The 
organic layer was washed with distilled water (15 mL), 
brine (2 × 15 mL), dried over anhydrous Na2SO4 and the 
solvent was removed under vacuum. The residue was 
purified by flash silica gel column chromatography (ethyl 
acetate:hexanes, up to 30:70) to provide the MBH adducts 
in good to high yields.
(±)-Methyl 2-[hydroxy(2-nitrophenyl)methyl]prop-
2-enoate (3): 92% yield, pale yellow oil; IR (film) 
nmax/cm-1: 3469, 1716, 1630, 1528, 1352; 1H NMR 
(500 MHz, CDCl3): d 7.94 (dd, J 1.2/8.2 Hz, 1H), 7.78 (d, 
1H, J 7.9 Hz), 7.61-7.67 (m, 1H), 7.41-7.48 (m, 1H), 6.36 
(s, 1H), 6.20 (s, 1H), 5.72 (s, 1H), 3.73 (s, 3H), 3.08 (s, 
1H, OH); 13C NMR (125 MHz, CDCl3): d 166.3, 148.2, 
140.7, 136.0, 133.4, 128.8, 128.6, 126.4, 124.5, 67.6, 




prop-2-enoate (4): 89% yield, colorless oil; IR (film) 













AcOH, CH2Cl2, 10% Pd/C













Scheme 6. Diastereoselective total synthesis of (+/-)-spisulosine from acyloin.
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(250 MHz, CDCl3): d 7.36 (s, 1H), 7.21-7.26 (m, 3H), 6.34 
(s, 1H), 5.84 (s, 1H), 5.49 (s, 1H), 3.71 (s, 3H), 3.16 (s, 
1H, OH); 13C NMR (62.5 MHz, CDCl3): d 166.6, 143.4, 
141.4, 134.3, 129.7, 127.9, 126.7, 124.8, 72.6, 52.1; HRMS 




(5): 75% yield, oil; IR (film) nmax/cm-1: 3448, 2949, 1711, 
1446, 1270, 1155, 1041; 1H NMR (250 MHz, CDCl3): 
d 7.21-7.37 (m, 5H), 6.31 (s, 1H), 5.86 (s, 1H), 5.52 (s, 
1H), 3.65 (s, 3H), 3.45 (s, 1H, OH); 13C NMR (62.5 MHz, 
CDCl3): d 166.7, 142.1, 141.4, 128.4, 127.8, 126.7, 
125.8, 72.8, 51.9; HRMS (ESI TOF) Calcd. for C11H12O3 
[M + Na+]: 215.0684. Found: 215.0811.
(±)-Methyl 2-[hydroxy(4-methoxyphenyl)methyl]prop-
2-enoate (6): 73% yield; amorphous solid; mp 70-72 °C; 
IR (KBr) nmax/cm-1: 3465, 1714, 1611, 1512, 1465, 1034; 
1H NMR (250 MHz, CDCl3): d 7.29 (d, 2H, J 8.5 Hz), 
6.87 (d, 2H, J 8.5 Hz), 6.32 (s, 1H), 5.85 (s, 1H), 5.53 (s, 
1H), 3.80 (s, 3H), 3.72 (s, 3H), 2.43 (s, 1H, OH); 13C NMR 
(62.5 MHz, CDCl3): d 166.8, 159.2, 142.1, 133.4, 127.9, 
125.7, 113.8, 72.8, 55.2, 51.9; HRMS (ESI TOF) Calcd. for 
C12H14O4 [M + Na
+]: 245.0784. Found: 245.0780.
(±)-Methyl 2-[hydroxy(3,4,5-trimethoxyphenyl)methyl]
prop-2-enoate (7): 60% yield; amorphous solid; mp 121-
123 ºC; IR (KBr) nmax/cm-1: 3464, 1712, 1613, 1514, 1463, 
1036; 1H NMR (250 MHz, CDCl3): d 6.54 (s, 2H), 6.27 
(s, 1H), 5.81 (s, 1H), 5.44 (d, 1H, J 5.0 Hz), 3.78 (s, 6H), 
3.77 (s, 3H), 3.69 (s, 3H), 3.35 (d, 1H, J 5.0 Hz); 13C NMR 
(62.5 MHz, CDCl3): d 166.8, 153.1, 141.9, 137.2, 137.0, 
125.9, 103.5, 72.9, 60.7, 55.9, 52.0; HRMS (ESI TOF) Calcd. 
for C11H11O3Cl [M + Na
+]: 305.0996. Found: 305.0989.
(±)-Methyl 2-[hydroxy(thiophen-2-yl)methyl]prop-
2-enoate (8): 90% yield; pale yellow oil; IR (film) nmax/cm-1: 
3445, 2952, 1715, 1632; 1H NMR (250 MHz, CDCl3): d 7.21 
(dd, 1H, J 2.5/3.8 Hz), 6.90-6.93 (m, 2H), 6.32 (s, 1H), 5.95 
(s, 1H), 5.73 (d, 1H, J 6,2 Hz), 3.73 (d, 1H, J 6.2 Hz), 3.70 
(s, 3H); 13C NMR (62.5 MHz, CDCl3): d 166.5, 145.8, 141.5, 
126.8, 126.0, 125.2, 124.8, 69.1, 52.0; HRMS (ESI TOF) 
Calcd. for C9H11O3S [M + H]
 +: 199.0423. Found: 199.0417.
(±)-Methyl 2-[(2-fluorophenyl)(hydroxy)methyl]prop-
2-enoate (9): 95% yield; colorless oil; IR (film) nmax/cm-1: 
3437, 1721; 1H NMR (250 MHz, CDCl3): d 7.42 (dt, 1H, 
J 1.9/7.5 Hz), 7.21-7.28 (m, 1H), 7.10 (dt, 1H, J 1.2/7.5 Hz), 
6.97-7.05 (m, 1H), 6.31 (s, 1H), 5.85 (d, 1H, J 5.5 Hz), 5.76 
(s, 1H), 3.69 (s, 3H), 3.62 (d, 1H, J 5.5 Hz); 13C NMR (62.5 
MHz, CDCl3): d 166.7, 160.0 (d, J 245.5 Hz), 140.9, 129.4 
(d, J 8.2 Hz), 128.4, 128.1 (d, J 3.7 Hz), 126.3, 124.1 (d, J 
3.5 Hz), 115.3 (d, J 21.5 Hz), 66.7, 52.0; HRMS (ESI TOF) 
Calcd. for C11H12FO3 [M + H]
 +: 211.0765. Found: 211.0762.
(±)-Methyl 3-hydroxy-2-methylenepentanoate (10): 
80% yield; colorless oil; IR (film) nmax/cm-1: 3454, 2928, 
2853, 1705, 1287, 1157; 1H NMR (250 MHz, CDCl3): 
d 6.15 (s, 1H), 5.74 (s, 1H), 4.27 (q, 1H, J 5.7 Hz), 3.69 (s, 
3H), 3.00 (d, 1H, J 5.7 Hz), 1.45-1.71 (m, 2H), 0.86 (t, 3H, 
J 7.4 Hz); 13C NMR (62.5 MHz, CDCl3): d 167.0, 142.3, 
124.9, 72.4, 51.7, 29.0, 9.9; HRMS (ESI TOF) Calcd. for 
C7H13O3[M + H]
 +: 145.0859. Found: 145.0856.
(±)-Methyl 3-hydroxy-2-methylenenonanoate (11): 
76% yield; amorphous solid; mp 131-132 ºC; IR (KBr) 
nmax/cm-1: 3452, 2929, 2855, 1707, 1290, 1155; 1H NMR 
(500 MHz, CDCl3): d 6.20 (s, 1H), 5.78 (s, 1H), 4.37 (t, 
1H, J 6.7 Hz), 3.77 (s, 3H), 1.54-1.71 (m, 2H), 1.19-1.50 
(m, 8H), 0.86 (t, 3H, J 6.7 Hz); 13C NMR (125 MHz, 
CDCl3): d 167.0, 142.5, 124.9, 71.7, 51.8, 36.2, 31.7, 29.0, 
25.7, 22.5, 14.0; HRMS (ESI TOF) Calcd. for C11H21O3 
[M + H]+: 201.1485. Found: 201.1483.
(±)-Methyl-3-hydroxy-2-methyleneoctadecanoate 
(12): 60% yield; amorphous solid; mp 43-45 °C; IR (film) 
nmax/cm-1: 3465, 2984, 2929, 2856, 1742, 1374, 1242, 1048; 
1H NMR (250 MHz, CDCl3): d 6.21 (s, 1H), 5.79 (t, 1H, 
J 1.0 Hz), 4.37 (q, 1H, J 6.5 Hz), 3.77 (s, 3H), 2.59 (d, 1H, 
J 6.5 Hz), 1.55-1.70 (m, 2H), 1.18-1.50 (m, 26H), 0.87 (t, 
3H, J 6.9 Hz); 13C NMR (62.5 MHz, CDCl3): d 167, 142.5, 
124.9, 71.8, 51.8, 36.2, 31.9, 29.7, 29.63, 29.6, 29.5, 29.4, 
29.3, 25.8, 22.7, 14.1; HRMS (ESI) Calcd. for C20H39O3 
[M + H]+ 327.2894; Found 327.2877.
General procedure for the silylation of Morita-Baylis-
Hillman adducts
A mixture of MBH adduct (1-3 mmol), imidazole 
(2.5 equiv.), TBSCl (1.5 equiv.) and a few drops of DMSO 
(to facilitate stirring), under argon atmosphere, was stirred 
at room temperature. After 2-4 h, the crude residue was 
diluted in ethyl acetate (25 mL). The organic layer was 
washed with distilled water (15 mL), brine (2 × 15 mL), 
dried over anhydrous Na2SO4 and the solvent was removed 
under vacuum. The crude mixture was filtered through silica 
gel (ethyl acetate:hexanes, 30:70) to provide the silylated 
compounds in good to excellent yields.
(±)-Methyl 2-{[(tert-butyldimethylsilyl)oxy](2-fluoro-
phenyl)methyl}prop-2-enoate (13): 97% yield; pale yellow 
Hyphenating the Curtius Rearrangement with Morita-Baylis-Hillman Adducts J. Braz. Chem. Soc.1576
oil; IR (film) nmax/cm-1: 2949, 2929, 2851, 1728, 1531, 1352, 
1249, 1090, 837; 1H NMR (250 MHz, CDCl3): d 7.78 (d, 
1H, J 8.0 Hz), 7.68 (d, 1H, J 8.0 Hz), 7.56 (t, 1H, J 7.5 Hz), 
7.37 (t, 1H, J 7.5 Hz), 6.34 (s, 1H), 6.29 (s, 1H), 5.97 (s, 
1H), 3.64 (s, 3H), 0.88 (s, 9H), 0.13 (s, 3H), −0.06 (s, 3H); 
13C NMR (62.5 MHz, CDCl3): d 165.2, 148.2, 143.1, 137.5, 
132.6, 129.6, 128.1, 125.0, 123.9, 66.7, 51.8, 25.7, 18.1, 




phenyl)methyl}prop-2-enoate (14): > 99% yield; pale 
yellow oil; IR (film) nmax/cm-1: 2949, 2929, 2855, 1707, 
1061, 841, 780; 1H NMR (250 MHz, CDCl3): d 7.35 (s, 
1H), 7.17-7.32 (m, 3H), 6.28 (s, 1H), 6.10 (s, 1H), 5.58 
(s, 1H), 3.69 (s, 3H), 0.88 (s, 9H), 0.06 (s, 3H), −0.08 (s, 
3H); 13C NMR (75.5 MHz, CDCl3): d 166.1, 144.8, 143.4, 
133.9, 129.3, 127.5, 127.0, 125.2, 124.4, 72.1, 51.7, 25.7, 
18.1, −5.0; HRMS (ESI TOF) Calcd. for C17H25ClO3Si 
[M + Na+]: 363.1154. Found: 363.1150.
(±)-Methyl 2-{[(tert-butyldimethylsilyl)oxy](phenyl)
methyl}prop-2-enoate (15): > 99% yield; colorless oil; IR 
(film) nmax/cm-1: 2949, 2851, 1458, 1258, 1082; 1H NMR 
(250 MHz, CDCl3): d 7.17-7.41 (m, 5H), 6.25 (s, 1H), 6.08 
(s, 1H), 5.61 (s, 1H), 3.68 (s, 3H), 0.88 (s, 9H), 0.06 (s, 
3H), −0.11 (s, 3H); 13C NMR (62.5 MHz, CDCl3): d 166.4, 
143.9, 142.6, 128.0, 127.3, 127.0, 123.8, 72.7, 51.6, 25.7, 
18.1, −4.9; HRMS (ESI TOF) Calcd. for C17H26O3Si [M + 
Na+]: 329.1543. Found: 329.1537.
(±)-Methyl 2-{[(tert-butyldimethylsilyl)oxy]
(4-methoxy phenyl)methyl}prop-2-enoate (16): > 99% 
yield; amorphous solid; mp 112-114 ºC; IR (KBr) nmax/cm-1: 
2949, 2929, 2851, 1715, 1507, 1245, 1047, 833, 771; 1H 
NMR (250 MHz, CDCl3): d 7.27 (d, 2H, J 7.0 Hz), 6.82 (d, 
2H, J 7.0 Hz), 6.22 (s, 1H), 6.06 (s, 1H), 5.56 (s, 1H), 3.78 
(s, 3H), 3.67 (s, 3H), 0.87 (s, 9H), 0.06 (s, 3H), −0.11 (s, 
3H); 13C NMR (125 MHz, CDCl3): d 166.4, 158.8, 144.1, 
134.8, 128.2, 123.3, 113.4, 72.3, 55.1, 51.6, 25.7, 18.1, 




(3,4,5-trimethoxy phenyl)methyl}prop-2-enoate (17): 80% 
yield; colorless oil; IR (film) nmax/cm-1: 2950, 2927, 2854, 
1718, 1505, 1246, 1051; 1H NMR (250 MHz, CDCl3): 
d 6.56 (s, 2H), 6.18 (t, 1H, J 1.1 Hz), 5.95 (t, 1H, J 1.5 Hz), 
5.53 (s, 1H), 3.78 (s, 6H), 3.67 (s, 3H), 0.85 (s, 9H), 0.03 (s, 
3H), −0.10 (s, 3H); 13C NMR (62.5 MHz, CDCl3): d 166.5, 
152.8, 143.9, 138.3, 137.0, 123.9, 103.7, 72.4, 60.7, 55.9, 
51.6, 25.6, 18.1, −4.9, −5.1; HRMS (ESI TOF) Calcd. for 
C20H32O6Si [M + Na
+]: 419.1860. Found: 419.1855.
(±)-Methyl 2-{[(tert-butyldimethylsilyl)oxy](thiophen-
2-yl)methyl}prop-2-enoate (18): 90% yield; colorless 
oil; IR (film) nmax/cm-1: 2954, 2930, 2857, 1723, 1632, 
1256, 1082; 1H NMR (250 MHz, CDCl3): d 7.18 (dd, 1H, 
J 5.0/1.3 Hz), 6.83-6.98 (m, 2H), 6.28 (t, 1H, J 1.1 Hz), 6.12 
(t, 1H, J 1.5 Hz), 5.89 (s, 1H), 3.73 (s, 3H), 0.90 (s, 9H), 
0.08 (s, 3H), −0.003 (s, 3H); 13C NMR (62.5 MHz, CDCl3): 
d 166.2, 147.3, 143.5, 126.3, 124.6, 124.4, 124.2, 68.4, 
51.7, 25.7, 18.2, −5.1, −5.14; HRMS (ESI TOF) Calcd. 
for C15H24O3SSi [M + Na
+]: 335.1108. Found: 335.1107.
(±)-Methyl 2-{[(tert-butyldimethylsilyl)oxy](2-fluoro-
phenyl)methyl}prop-2-enoate (19): 85% yield; colorless 
oil; IR (film) nmax/cm-1: 1723; 1H NMR (250 MHz, CDCl3): 
d 7.35 (dt, 1H, J 1.5/7.5 Hz), 7.16-7.28 (m, 1H), 6.95-7.14 
(m, 2H), 6.34 (s, 1H), 6.07 (s, 1H), 5.95 (s, 1H), 3.66 (s, 
3H), 0.87 (s, 9H), 0.08 (s, 3H), −0.09 (s, 3H); 13C NMR 
(62.5 MHz, CDCl3): d 166.0, 159.8 (d, J 245.7 Hz), 142.7, 
129.5 (d, J 13.5 Hz), 129.1, 129.0 (d, J 6.8 Hz), 128.8, 
124.8, 123.9 (d, J 3.5 Hz), 115.2 (d, J 22.2 Hz), 65.8, 51.6, 
25.7, 18.1, −5.2, −5.3.
(±)-Methyl 3-[(tert-butyldimethylsilyl)oxy]-
2-methylidene pentanoate (20): 85% yield; colorless oil; 
IR (film) nmax/cm-1: 2930, 2845, 1721; 1H NMR (250 MHz, 
CDCl3): d 6.20-6.23 (m, 1H), 5.86-5.89 (m, 1H), 4.50-4.59 
(m, 1H), 3.74 (s, 3H), 1.35-1.75 (m, 2H), 0.90 (s, 9H), 0.85 
(t, 3H, J 7.4 Hz), 0.05 (s, 3H), −0.02 (s, 3H); 13C NMR 
(62.5 MHz, CDCl3): d 166.8, 143.6, 124.5, 71.0, 51.6, 
30.3, 25.8, 18.1, 9.0, −4.8, –5.1; HRMS (ESI TOF) Calcd. 
for C17H25FO3Si [M + Na
+]: 347.1449 Found: 347.1445.
(±)-Methyl 3-[(tert-butyldimethylsilyl)oxy]-
2-methylidenenonanoate (21): > 99% yield; amorphous 
solid; mp 102-103 ºC; IR (film) nmax/cm-1: 2929, 2859, 
1719, 1249, 1090, 837; 1H NMR (250 MHz, CDCl3): 
d 6.17-6.21 (m, 1H), 5.87-5.90 (m, 1H), 4.52-4.61 (m, 
1H), 3.72 (s, 3H), 1.18-1.65 (m, 10H), 0.78-0.92 (m, 12H), 
0.04 (s, 3H), −0.04 (s, 3H); 13C NMR (62.5 MHz, CDCl3): 
d 166.7, 144.1, 124.2, 70.2, 51.5, 37.8, 31.8, 29.1, 25.7, 
24.9, 22.6, 18.1, 14.0, −4.8, −5.1; HRMS (ESI TOF) Calcd. 
for C17H34O3Si [M + Na
+]: 337.2169. Found: 337.2168.
(±)-Methyl-3-[(tert-butyldimethylsi lyl)oxy]-
2-methyleneoctadecanoate (22): 70% yield; viscous 
colorless oil; IR (film) nmax/cm-1: 2926, 2855, 1722, 1463, 
1257, 1092; 1H NMR (250 MHz, CDCl3): d 6.19-6.21 (m, 
1H), 5.90 (t, 1H, J 1.6 Hz), 4.56-4.61 (m, 1H), 3.75 (s, 3H), 
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1.18-1.63 (m, 28H), 0.81-0.93 (m, 12H), 0.05 (s, 3H), −0.02 
(s, 3H); 13C NMR (62.5 MHz, CDCl3): d 166.7, 144.2, 124.2, 
70.2, 51.6, 37.9, 31.9, 29.7, 29.63, 29.6, 29.55, 29.5, 29.3, 
25.8, 22.7, 18.1, 14.1, −4.8, −5.1; HRMS (ESI TOF) Calcd. 
for C26H52O3Si [M + Na]
+: 463.3578. Found: 463.3572.
General procedure for hydrolysis of silylated esters
To a solution of silylated MBH adduct (1-3 mmol) 
in a mixture of water:acetonitrile (1:1) was added LiOH 
(10 equiv.). The resulting solution was stirred for 4 h at 
50-60 oC. Then, the solvents were removed under reduced 
pressure and the crude mixture was extracted with ethyl 
acetate. The organic layer was dried over anhydrous Na2SO4 
and the solvent was removed under vacuum. The residue 
was filtered through silica gel (ethyl acetate as solvent) 
to provide the corresponding carboxylic acids in almost 
quantitative yields, for most cases > 99%.
(±)-2-{[(tert-Butyldimethylsilyl)oxy](2-nitrophenyl)
methyl}prop-2-enoic acid (23): 97% yield; viscous pale 
yellow oil; IR (film) nmax/cm-1: 2945, 2864, 2353, 1703, 1531, 
1258, 1090, 837; 1H NMR (250 MHz, CDCl3): d 7.81 (d, 
1H, J 8.0 Hz), 7.71 (d, 1H, J 8.0 Hz), 7.57 (t, 1H, J 7.5 Hz), 
7.38 (t, 1H, J 7.5 Hz), 6.40 (s, 1H), 6.34 (s, 1H), 6.04 (s, 1H), 
0.90 (s, 9H), 0.13 (s, 3H), 0.05 (s, 3H); 13C NMR (62.5 MHz, 
CDCl3): d 170.4, 148.1, 142.4, 137.3, 132.7, 129.5, 128.2, 
127.2, 124.0, 66.6, 25.7, 18.1, −4.9; HRMS (ESI TOF) Calcd. 
for C16H23NO5Si [M + Na
+]: 360.1238. Found: 360.1237.
(±)-2-{[(tert-Butyldimethylsilyl)oxy](3-chlorophenyl)
methyl}prop-2-enoic acid (24): 99% yield; viscous colorless 
oil; IR (film) nmax/cm-1: 2949, 2929, 2851, 1691, 1437, 1254, 
1074, 833, 780; 1H NMR (250 MHz, CDCl3): d 7.34 (s, 1H), 
7.18-7.29 (m, 3H), 6.43 (s, 1H), 6.19 (s, 1H), 5.54 (s, 1H), 
0.88 (s, 9H), 0.06 (s, 3H), −0.07 (s, 3H); 13C NMR (62.5 
MHz, CDCl3): d 170.1, 144.4, 142.6, 134.0, 129.4, 127.7, 
127.0, 125.1, 71.9, 25.7, 18.1, −5.0; HRMS (ESI TOF) Calcd. 
for C16H23O3ClSi [M + Na
+]: 349.0918. Found: 349.1003.
(±)-2-{[(tert-Butyldimethylsilyl)oxy](phenyl)methyl}
prop-2-enoic acid (25): 99% yield; yellowish oil; 1H NMR 
(250 MHz, CDCl3): d 7.20-7.41 (m, 5H), 6.39 (s, 1H), 6.13 
(s, 1H), 5.58 (s, 1H), 0.88 (s, 9H), 0.07 (s, 3H), −0.07 (s, 
3H); 13C NMR (62.5 MHz, CDCl3): d 169.8, 142.9, 141.9, 
128.1, 127.6, 126.8, 126.4, 72.8, 25.7, 18.2, −5.0; HRMS 




methyl}prop-2-enoic acid (26): 98% yield; viscous 
colorless oil; IR (film) nmax/cm-1: 2953, 2925, 2847, 1691, 
1507, 1245, 1074, 837, 775; 1H NMR (250 MHz, CDCl3): 
d 7.25 (d, 2H, J 7.0 Hz), 6.82 (d, 2H, J 7.0 Hz), 6.35 (s, 
1H), 6.11 (s, 1H), 5.52 (s, 1H), 3.79 (s, 3H), 0.89 (s, 9H), 
0.09 (s, 3H), -0.06 (s, 3H); 13C NMR (125 MHz, CDCl3): 
d 170.1, 158.9, 143.1, 134.2, 128.1, 126.0, 113.5, 72.4, 
55.2, 25.7, 18.1, −4.9, −5.1; HRMS (ESI TOF) Calcd. for 
C17H26O4Si [M + Na
+]: 345.1493. Found: 345.1490.
(±)-2-{[(tert-Butyldimethylsilyl)oxy](3,4,5-trimethoxy-
phenyl)methyl}prop-2-enoic acid (27): 99% yield; viscous 
oil; IR (film) nmax/cm-1: 2955, 2923, 2849, 1692, 1509, 1243, 
1077; 1H NMR (250 MHz, CDCl3): d 6.58 (s, 2H), 6.37 (s, 
1H), 6.08 (s, 1H), 5.53 (s, 1H), 3.81 (s, 9H), 0.89 (s, 9H), 
0.06 (s, 3H), −0.05 (s, 3H); 13C NMR (62.5 MHz, CDCl3): 
d 170.9, 152.8, 143.3, 137.9, 137.1, 126.4, 103.7, 72.3, 
60.8, 56.0, 25.7, 18.2, −4.9, −5.1; HRMS (ESI TOF) 
Calcd. for C19H30O6Si [M + Na
+]: 405.1709. Found: 
405.1566.
(±)-2-{[(tert-Butyldimethylsilyl)oxy](thiophen-3-yl)
methyl}prop-2-enoic acid (28): 99% yield; viscous 
colorless oil; IR (film) nmax/cm-1: 2959, 2931, 2857, 1691, 
1459, 1259, 1074, 837; 1H NMR (250 MHz, CDCl3): 
d 7.20 (dd, 1H, J 5.0/1.3 Hz), 6.85-6.97 (m, 2H), 6.45 (t, 
1H, J 1.0 Hz), 6.23 (t, 1H, J 1.3 Hz), 5.87 (s, 1H), 0.92 
(s, 9H), 0.10 (s, 3H), 0.02 (s, 3H); 13C NMR (62.5 MHz, 
CDCl3): d 170.8, 146.9, 142.8, 126.9, 126.4, 124.8, 124.5, 
68.3, 25.7, 18.2, −5.1, −5.14; HRMS (ESI TOF) Calcd. 
for C14H22O3SSi [M + Na
+]: 321.0957. Found: 321.0883.
(±)-2-{[(tert-Butyldimethylsilyl)oxy](2-fluorophenyl)
methyl}prop-2-enoic acid (29): 99% yield; colorless oil; 
IR (film) nmax/cm-1: 2951, 2928, 2850, 1692, 1072, 832, 782; 
1H NMR (250 MHz, CDCl3): d 10.44 (s, 1H, COOH), 7.34 
(dt, 1H, J 1.8/7.5 Hz), 7.18-7.29 (m, 1H), 6.95-7.15 (m, 
2H), 6.47 (s, 1H), 6.16 (s, 1H), 5.92 (s, 1H), 0.87 (s, 9H), 
0.09 (s, 3H), −0.08 (s, 3H); 13C NMR (62.5 MHz, CDCl3): 
d 171.0, 159.8 (d, J 246.1 Hz), 142.1, 129.3 (d, J 3.0 Hz), 
129.1 (d, J 2.1 Hz), 128.8 (d, J 3.8 Hz), 127.3, 123.9 (d, 
J 3.5 Hz), 115.3 (d, J 22.0 Hz), 65.7, 51.6, 25.7, 18.1, 
−5.2, −5.24; HRMS (ESI TOF) Calcd. for C16H23O3FSi 
[M + Na+]: 333.1298. Found: 333.1207.
(±)-3-[(tert-Butyldimethylsilyl)oxy]-2-methylidene-
pentanoic acid (30): fluid oil; 99% yield; IR (film) nmax/cm-1: 
2923, 2854, 1691, 1253, 1084; 1H NMR (250 MHz, CDCl3): 
d 11.60 (s, 1H, COOH), 6.41 (d, 1H, J 1.2 Hz), 6.00 (t, 
1H, J 1.5 Hz), 4.55 (t, 1H, J 5.4 Hz), 1.41-1.80 (m, 2H), 
0.78-1.00 (m, 12H), 0.08 (s, 3H), 0.01 (s, 3H); 13C NMR 
(62.5 MHz, CDCl3): d 171.6, 142.9, 127.2, 71.2, 30.3, 29.1, 
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25.7, 18.1, 9.1, −4.9, −5.1; HRMS (ESI TOF) Calcd. for 
C12H24O3Si [M + H
+]: 245.1573. Found: 245.1554.
(±)-3-[(tert-Butyldimethylsilyl)oxy]-2-methylidene-
nonanoic acid (31): 98% yield; fluid oil; IR (film) nmax/cm-1: 
2925, 2859, 1691, 1254, 1086, 833, 649; 1H NMR 
(250 MHz, CDCl3): d 6.37 (s, 1H), 5.92 (s, 1H), 4.51-4.59 
(m, 1H), 1.20-1.40 (m, 10H), 0.82-0.93 (m, 12H), 0.08 
(s, 3H), 0.02 (s, 3H); 13C NMR (62.5 MHz, CDCl3), d: 
170.6, 142.9, 126.9, 71.2, 37.7, 31.7, 29.1, 25.7, 25.0, 22.6, 
18.1, 14.1, −5.0; HRMS (ESI TOF) Calcd. for C16H32O3Si 
[M + H+]: 301.2199. Found: 301.2232.
(±)-3-[(tert-Butyldimethylsilyl)oxy]-2-methylene-
octadecanoic acid (32): 99% yield; white solid; mp 
45-47 °C; IR (film) nmax/cm-1: 2918, 2851, 1681, 1623, 1472, 
1090, 838; 1H NMR (250 MHz, CDCl3): d 6.34-6.36 (m, 1H), 
5.86-5.88 (m, 1H), 4.53 (t, 1H, J 5.6 Hz), 1.45-1.63 (m, 2H), 
1.18-1.39 (m, 26H), 0.83-0.93 (m, 12H), 0.1 (s, 3H), 0.03 (s, 
3H); 13C NMR (62.5 MHz, CDCl3): d 169.7, 142.5, 126.8, 
71.8, 37.6, 31.9, 29.7, 29.64, 29.6, 29.5, 29.5, 29.4, 29.3, 
25.8, 25.1, 22.7, 18.1, 14.1, −4.8, −5.0; HRMS (ESI TOF) 
Calcd. for C25H50O3Si [M + H]
+: 427.3607. Found: 427.3599.
General procedure for the preparation of a-hydroxyketones 
(acyloins)
To a stirred 0.2 mol L-1 solution of carboxylic acid in 
acetone at 0 ºC was added triethylamine (2 equiv.) and 
ethyl chloroformate (1.5 equiv.). The mixture was stirred at 
0 ºC and carbonate formation was observed by TLC after 
5 min. After that, NaN3 was added (2.5 equiv.). The resulting 
mixture was vigorously stirred for 2 h until the formation 
of a slightly apolar layer (acylazide formation). Then, the 
crude mixture was diluted in cold dichloromethane and 
washed with cold water. The organic layer was dried over 
anhydrous Na2SO4 and the solvent was removed under 
vacuum. To this crude material, under an argon atmosphere, 
dry toluene (0.1 mol L-1) was added and the mixture was 
refluxed for 2 h. The solvent was then removed under reduced 
pressure and the resulting product was diluted in water. The 
mixture was refluxed for 12 h. Then, the reaction mixture 
was coolled to room temperature and extracted with ethyl 
acetate. The organic layer was dried over anhydrous Na2SO4 
and the solvent was removed under vacuum. The residue 
was purified by flash silica gel column chromatography 
(ethyl acetate:hexanes, up to 25:75) to provide the required 
acyloins. Yields refer to 3 steps from MBH adducts.
(±)-1-[(tert-Butyldimethylsilyl)oxy]-1-(2-nitrophenyl)
propan-2-one (33): 46% yield; pale yellow oil; IR (film) 
nmax/cm-1: 2953, 2933, 2851, 1728, 1527, 1343, 1254, 
1102, 833; 1H NMR (250 MHz, CDCl3): d 7.97-8.03 (m, 
1H), 7.58-7.77 (m, 2H), 7.42-7.51 (m, 1H), 5.72 (s, 1H), 
2.31 (s, 3H), 0.91 (s, 9H), 0.16 (s, 3H), −0.07 (s, 3H); 
13C NMR (62.5 MHz, CDCl3): d 205.8, 147.7, 135.0, 
133.2, 129.2, 128.8, 124.8, 26.3, 25.6, 18.1, −5.0; HRMS 




propan-2-one (34): 45% yield; colorless oil; IR (film) 
nmax/cm-1: 2953, 2929, 2864, 1719, 1470, 1258, 1111, 775; 
1H NMR (250 MHz, CDCl3): d 7.43 (s, 1H), 7.23-7.33 
(m, 3H), 5.00 (s, 1H), 2.12 (s, 3H), 0.96 (s, 9H), 0.09 (s, 
3H), 0.02 (s, 3H); 13C NMR (62.5 MHz, CDCl3): d 208.5, 
140.7, 134.5, 129.8, 128.2, 125.9, 123.9, 80.6, 25.7, 23.9, 
18.2, −4.9; HRMS (ESI TOF) Calcd. for C15H23O2ClSi 
[M + Na+]: 321.1053. Found: 321.1056
(±)-1-[(tert-Butyldimethylsilyl)oxy]-1-phenylpropan-
2-one (35): 50% yield; pale yellow oil; IR (film) nmax/cm-1: 
2949, 2929, 2855, 1711, 1258, 1102, 865, 837; 1H NMR 
(250 MHz, CDCl3): d 7.25-7.45 (m, 5H), 5.04 (s, 1H), 
2.11 (s, 3H), 0.96 (s, 9H), 0.10 (s, 3H), 0.01 (s, 3H); 
13C NMR (125 MHz, CDCl3): d 209.1, 199.5, 138.6, 128.5, 
128.0, 125.8, 81.2, 25.7, 23.9, 18.2, −4.9, −5.2; HRMS 




phenyl)propan-2-one (36): 48% yield; pale yellow oil; 
IR (film) nmax/cm-1: 2949, 2855, 1715, 1511, 1090, 841, 
784; 1H NMR (250 MHz, CDCl3): d 7.30 (d, 2H, J 6.7 Hz), 
6.87 (d, 2H, J 6.7 Hz), 4.99 (s, 1H), 3.80 (s, 3H), 2.11 (s, 
3H), 0.94 (s, 9H), 0.08 (s, 3H), −0.01 (s, 3H); 13C NMR 
(62.5 MHz, CDCl3): d 209.2, 159.4, 130.7, 127.1, 113.9, 
80.8, 55.2, 25.7, 23.8, 18.2, −5.0; HRMS (ESI TOF) Calcd. 
for C16H26O3Si [M + Na
+]: 317.1549. Found: 317.1505.
(±)-1-[(tert-Butyldimethylsilyl)oxy]-1-(3,4,5-
trimethoxy phenyl)propan-2-one (37): 42% yield; colorless 
oil; IR (film) nmax/cm-1: 2947, 2853, 1714, 1512, 1089, 843; 
1H NMR (250 MHz, CDCl3): d 6.65 (s, 2H), 4.95 (s, 1H), 
3.75-3.88 (m, 9H), 2.10 (s, 3H), 0.95 (s, 9H), 0.07 (s, 3H), 
0.03 (s, 3H); 13C NMR (62.5 MHz, CDCl3): d 208.8, 153.3, 
137.5, 134.0, 102.4, 80.9, 60.8, 56.0, 25.7, 23.7, 18.2, −4.9, 




propan-2-one (38): 44% yield; pale yellow oil; IR (film) 
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nmax/cm-1: 2949, 2851, 1712, 1091; 1H NMR (250 MHz, 
CDCl3): d 7.22-7.28 (m, 1H), 6.96-7.01 (m, 2H), 5.24 (s, 
1H), 2.20 (s, 3H), 0.95 (s, 9H), 0.10 (s, 3H), 0.05 (s, 3H); 
13C NMR (62.5 MHz, CDCl3): d 207.7, 153.3, 142.6, 127.1, 
125.2, 124.3, 77.8, 25.6, 23.7, 18.2, −5.1, −5.2; HRMS 




propan-2-one (39): 41% yield; colorless oil; IR (film) 
nmax/cm-1: 2951, 1720, 1471, 1256, 1109; 1H NMR 
(250 MHz, CDCl3): d 7.47 (dt, 1H, J 1.8/7.5 Hz), 7.23-7.35 
(m, 1H), 7.15 (dt, 1H, J 1.2/7.5 Hz), 7.00-7.09 (m, 1H), 
5.34 (s, 1H), 2.18 (s, 3H), 0.92 (s, 9H), 0.11 (s, 3H), −0.05 
(s, 3H); 13C NMR (62.5 MHz, CDCl3): d 207.1, 159.8 (d, 
J 245.4 Hz), 129.8 (d, J 8.1 Hz), 128.2 (d, J 3.8 Hz), 126.6 
(d, J 14.3 Hz), 124.3 (d, J 3.5 Hz), 115.4 (d, J 21.5 Hz), 
74.9, 25.6, 24.9, 18.1, −5.1, −5.2; HRMS (ESI TOF) Calcd. 
for C15H23O2FSi [M + Na
+]: 305.1349. Found: 305.1284.
(±)-3-[(tert-Butyldimethylsilyl)oxy]pentan-2-one (40): 
46% yield; colorless oil; 1H NMR (250 MHz, CDCl3): 
d 3.90 (dd, 1H, J 5.6/6.5 Hz), 2.13 (s, 3H), 1.50-1.71 
(m, 2H), 0.77-0.93 (m, 12H), 0.04 (s, 3H), 0.03 (s, 3H); 
13C NMR (62.5 MHz, CDCl3): d 212.5, 79.9, 27.8, 25.3, 
18.0, 9.1, −5.0, −5.1; HRMS (ESI TOF) Calcd. for 
C11H24O2Si [M + H
+]: 217.1624. Found: 217.1608.
(±)-3-[(tert-Butyldimethylsilyl)oxy]nonan-2-one (41): 
42% yield; pale yellow oil; 1H NMR (250 MHz, CDCl3): 
d 3.92-4.03 (m, 1H), 2.15 (s, 3H), 1.18-1.45 (m, 10H), 0.82-
1.09 (m, 12H), 0.05 (s, 6H); 13C NMR (62.5 MHz, CDCl3): 
d 212.8, 79.0, 34.8, 31.7, 29.2, 25.7, 25.2, 24.7, 22.6, 18.1, 
14.1, −4.9; HRMS (ESI TOF) Calcd. for C15H32O2Si [M + 
Na+]: 295.4887. Found: 295.4849.
(±)-3-[(tert-Butyldimethylsilyl)oxy]octadecan-2-one 
(42): 40% yield; colorless viscous oil; IR (film) nmax/cm-1: 
2926, 2855, 1719, 1465, 1253, 1104; 1H NMR (250 MHz, 
CDCl3): d 3.97 (dd, 1H, J 5.3/6.9 Hz), 2.15 (s, 3H), 1.46-
1.55 (m, 2H), 1.17-1.40 (m, 26H), 0.83-0.97 (m, 12H), 0.06 
(s, 3H), 0.05 (s, 3H); 13C NMR (62.5 MHz, CDCl3): d 212.7, 
79.0, 34.8, 31.9, 29.7, 29.64, 29.6, 29.5, 29.4, 29.3, 25.7, 
25.2, 24.7, 22.7, 18.1, 14.1, −5.0; HRMS (ESI TOF) Calcd. 
for C24H50O2Si [M + Na
+]: 421.3478. Found: 421.3453.
General procedure for the diastereoselective preparation 
of vicinal alcohols
To a 0.2 mol L-1 methanolic solution of acyloins was 
added an amine (3 equiv.). The resulting solution was 
vigorously stirred at room temperature for 1 h. After, the 
solution was cooled to −78 oC and LiBH4 (1.2 equiv.) 
was added. The mixture was then warmed to room 
temperature and stirred for 12 h. Then, the medium was 
diluted with ethyl acetate (15 mL) and the organic phase 
was washed with water (5 × 7 mL), brine (10 mL), dried 
over anhydrous Na2SO4 and the solvent was removed 
under vacuum. The residue was purified through silica gel 
(solvent: hexanes:ethyl acetate, up to 65:35) to provide the 




79% yield; yellowish oil; IR (film) nmax/cm-1: 2955, 2929, 
2857, 1471, 1254, 1075, 836; 1H NMR (250 MHz, CDCl3): 
d 7.08-7.32 (m, 9H), 4.55 (d, 1H, J 4.7 Hz), 2.62-2.99 (m, 
5H), 0.98 (d, 3H, J 6.4 Hz), 0.86 (s, 9H), −0.003 (s, 3H), 
−0.20 (s, 3H); 13C NMR (62.5 MHz, CDCl3): d 145.1, 139.9, 
133.9, 129.2, 128.6, 128.4, 127.3, 126.8, 126.1, 124.8, 
77.0, 59.7, 48.6, 36.5, 25.8, 18.1, 14.9, −4.6, −5.1; HRMS 




1-(3-chlorophenyl)propan-2-yl]amine (44): 77% yield; 
yellowish oil. IR (film) nmax/cm-1: 2929, 2857, 1471, 1255, 
1075, 836; 1H NMR (250 MHz, CDCl3): d 7.12-7.37 (m, 
9H), 4.63 (d, 1H, J 4.8 Hz), 3.82 (d, 1H, J 13.5 Hz), 3.71 
(d, 1H, J 13.5 Hz), 2.77 (dq, 1H, J 4.8/6.4 Hz), 1.02 (d, 
3H, J 6.4 Hz), 0.89 (s, 9H), 0.05 (s, 3H), −0.16 (s, 3H); 
13C NMR (62.5 MHz, CDCl3): d 145.2, 140.4, 133.9, 129.2, 
128.3, 127.8, 127.3, 127.0, 126.8, 125.0, 77.1, 58.6, 51.0, 
25.8, 18.1, 15.1, −4.6, −4.9; HRMS (ESI TOF) Calcd. for 
C22H32ONClSi [M + H
+]: 390.2020. Found: 370.1797.
(±)-1,2-anti-{1-[(tert-Butyldimethylsilyl)oxy]- 
1-phenylpropan-2-yl}(2-phenylethyl)amine (45): 85% 
yield; yellowish oil; IR (film) nmax/cm-1: 2928, 2857, 1453, 
1255, 1063, 836; 1H NMR (250 MHz, CDCl3): d 7.09-7.32 
(m, 10H), 4.58 (d, 1H, J 5.0 Hz), 2.61-2.99 (m, 5H), 1.02 
(d, 3H, J 6.4 Hz), 0.86 (s, 9H), −0.001 (s, 3H), −0.22 (s, 
3H); 13C NMR (62.5 MHz, CDCl3): d 142.9, 140.0, 128.6, 
128.4, 127.9, 127.1, 126.7, 126.0, 77.6, 59.8, 48.7, 36.6, 
25.8, 18.1, 15.1, −4.6, −5.1; HRMS (ESI TOF) Calcd. for 
C23H35ONSi [M + H
+]: 370.2566. Found: 370.2747.
(±)-1,2-anti-Benzyl({1-[(tert-butyldimethylsilyl)oxy]- 
1-phenylpropan-2-yl})amine (46): 83% yield; yellowish oil; 
IR (film) nmax/cm-1: 2956, 2929, 2857, 1493, 1254, 1063, 
1028, 836; 1H NMR (250 MHz, CDCl3): d 7.12-7.38 (m, 
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10H), 4.64 (d, 1H, J 5.1 Hz), 3.81 (d, 1H, J 13.5 Hz), 3.72 
(d, 1H, J 13.5 Hz), 2.80 (dq, 1H, J 5.1/6.4 Hz), 1.05 (d, 3H, 
J 6.4 Hz), 0.90 (s, 9H), 0.05 (s, 3H), −0.18 (s, 3H); 13C NMR 
(62.5 MHz, CDCl3): d 142.9, 140.6, 128.3, 127.9, 127.8, 
127.1, 126.9, 126.7, 77.8, 58.7, 51.0, 25.8, 18.2, 15.4, −4.5, 




1-phenylpropan-2-yl}(prop-2-en-1-yl)amine (47): 82% 
yield; yellowish oil; IR (film) nmax/cm-1: 2956, 2929, 2857, 
1471, 1255, 1063, 867, 837; 1H NMR (250 MHz, CDCl3): 
d 7.17-7.42 (m, 5H), 5.73-5.95 (m, 1H), 5.00-5.21 (m, 2H), 
4.65 (d, 1H, J 4.8 Hz), 3.12-3.39 (m, 2H), 2.80 (dq, 1H, 
J 4.8/6.4 Hz), 0.99 (d, 3H, J 6.4 Hz), 0.90 (s, 9H), 0.05 (s, 
3H), −0.19 (s, 3H); 13C NMR (62.5 MHz, CDCl3): d 142.9, 
137.0, 128.3, 127.9, 127.1, 126.7, 115.4, 77.3, 58.9, 49.6, 
25.8, 18.2, 14.9, −4.5, −5.0; HRMS (ESI TOF) Calcd. for 
C18H31ONSi [M + H
+]: 306.2253. Found: 306.2394.
(±)-1,2-anti-N-{1-[(tert-Butyldimethylsilyl)oxy]- 
1-phenylpropan-2-yl}cyclohexanamine (48): 80% yield; 
yellowish oil; IR (film) nmax/cm-1: 2928, 2855, 1451, 1255, 
1066, 862, 836; 1H NMR (250 MHz, CDCl3): d 7.15-7.40 
(m, 5H), 4.61 (d, 1H, J 4.7 Hz), 2.89 (dq, 1H, J 4.7/6.3 Hz), 
2.41-2.60 (m, 1H), 1.50-1.92 (m, 6H), 1.09-1.35 (m, 4H), 
0.97 (d, 3H, J 6.3 Hz), 0.90 (s, 9H), 0.04 (s, 3H), −0.20 (s, 
3H); 13C NMR (62.5 MHz, CDCl3): d 143.3, 127.8, 127.0, 
77.5, 55.8, 52.9, 34.1, 33.1, 26.2, 25.6, 25.0, 24.9, 18.2, 
15.5, −4.5, −5.0; HRMS (ESI TOF) Calcd. for C21H37ONSi 
[M + H+]: 348.2723. Found: 348.2834.
(±)-1,2-anti-{1-[(tert-Butyldimethylsilyl)oxy]-1-
(3,4,5-trimethoxyphenyl)propan-2-yl}(2-phenylethyl)
amine (49): 81% yield; colorless oil; IR (film) nmax/
cm-1: 2933, 1592, 1455, 1321, 1128, 836, 776; 1H 
NMR  (250 MHz, CDCl3): d  7.05-7.27 (m, 5H), 
6.48 (s, 2H), 4.45 (d, 1H, J 5.4 Hz), 3.84 (s, 3H), 
3.81 (s,  6H), 2.62-3.00 (m, 5H), 1.05 (d,  3H, 
J 6.1 Hz), 0.86 (s, 9H), 0.01 (s, 3H), −0.19 (s, 3H); 
13C NMR (62.5 MHz, CDCl3): d 152.8, 139.8, 138.6, 
136.8, 128.5, 128.4, 126.1, 103.4, 77.9, 60.9, 59.9, 56.0, 
48.6, 36.4, 25.8, 18.1, 15.3, −4.5, −5.1; HRMS (ESI TOF) 
Calcd. for C26H41O4NSi [M + H




80% yield; colorless oil; IR (film) nmax/cm-1: 2930, 2857, 
1592, 1420, 1330, 1130, 869, 837; 1H NMR (250 MHz, 
CDCl3): d 6.54 (s, 2H), 5.75-5.92 (m, 1H), 5.01-5.17 (m, 
2H), 4.55 (d, 1H, J 5.0 Hz), 3.84 (s, 9H), 3.10-3.37 (m, 2H), 
2.80 (dq, 1H, J 5.0/6.3 Hz), 1.03 (d, 3H, J 6.3 Hz), 0.91 
(s, 9H), 0.06 (s, 3H), −0.14 (s, 3H); 13C NMR (62.5 MHz, 
CDCl3): d 152.8, 138.7, 136.9, 136.8, 115.4, 103.4, 77.6, 
60.9, 59.0, 56.0, 49.6, 25.8, 18.2, 15.1, −4.5, −5.0; HRMS 





82% yield; yellowish oil; IR (film) nmax/cm-1: 2955, 2929, 
2857, 1471, 1253, 1075, 836; 1H NMR (250 MHz, CDCl3): 
d 7.09-7.27 (m, 6H), 6.80-6.93 (m, 2H), 4.76 (d, J 5.6 Hz, 
1H), 2.63-2.99 (m, 5H), 1.08 (d, 3H, J 6.3 Hz), 0.85 (s, 9H), 
0.02 (s, 3H), −0.15 (s, 3H); 13C NMR (62.5 MHz, CDCl3): 
d 146.9, 140.0, 128.6, 128.4, 126.002, 126.0, 124.5, 124.3, 
74.7, 60.1, 48.7, 36.5, 25.7, 18.1, 15.9, −4.6, −5.1; HRMS 




fluorophenyl)propan-2-yl}(2-phenylethyl)amine (52): 78% 
yield; yellowish oil; IR (film) nmax/cm-1: 2857, 1486, 1254, 
1033, 837; 1H NMR (250 MHz, CDCl3): d 7.43 (dt, 1H, 
J1 1.8, J2 7.5 Hz), 7.05-7.35 (m, 8H), 6.90-7.01 (m, 1H), 
5.07 (d, 1H, J 3.9 Hz), 2.62-2.99 (m, 5H), 0.97 (d, 3H, 
J 6.5 Hz), 0.87 (s, 9H), 0.02 (s, 3H), 0.01 (s, 3H); 13C NMR 
(62.5 MHz, CDCl3): d 159.4 (d, J 242.8 Hz), 140.2, 130.0 
(d, J 13.3 Hz), 128.8 (m, C-Ar), 128.4 (m, C-Ar), 126.0, 
123.7 (d, J 3.4 Hz), 114.8 (d, J 22.0 Hz), 70.0, 58.3, 48.7, 
36.7, 25.8, 18.1, 14.8, −4.8, −5.2; HRMS (ESI TOF) Calcd. 
for C23H34ONFSi [M + H
+]: 388.2472. Found: 388.2512.
(±)-1,2-anti-{3-[(tert-Butyldimethylsilyl)oxy]pentan-
2-yl}(2-phenylethyl)amine (53): 73% yield; yellowish oil; 
IR (film) nmax/cm-1: 2958, 2930, 2857, 1470, 1254, 1007, 
835; 1H NMR (250 MHz, CDCl3): d 7.12-7.37 (m, 5H), 
3.49-3.60 (m, 1H), 2.60-2.99 (m, 5H), 1.38-1.52 (m, 2H), 
0.98 (d, 3H, J 6.5 Hz), 0.78-0.90 (m, 12H), 0.03 (s, 3H), 
−0.01 (s, 3H); 13C RMN (62.5 MHz, CDCl3): d 140.2, 128.7, 
128.4, 126.1, 76.6, 56.9, 49.3, 36.9, 25.8, 25.3, 18.0, 15.0, 
10.4, −4.4, −4.5; HRMS (ESI TOF) Calcd. for C19H35ONSi 
[M + H+]: 322.2566. Found: 322.2550.
(±)-1,2-anti-{3-[(tert-Butyldimethylsilyl)oxy]pentan- 
2-yl}(decyl)amine (54): 71% yield; yellowish oil; IR (film) 
nmax/cm-1: 2958, 2928, 2855, 1463, 1254, 836; 1H NMR 
(250 MHz, CDCl3): d 3.50-3.61 (m, 1H), 2.54-2.71 (m, 
2H), 2.38-2.51 (m, 1H), 1.38-1.60 (m, 6H), 1.26 (br, 16H), 
0.96 (d, 3H, J 6.5 Hz), 0.81-0.91 (m, 12H), 0.05 (s, 6H); 
13C NMR (62.5 MHz, CDCl3): d 76.6, 56.9, 47.8, 31.9, 30.4, 
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29.6, 29.5, 29.3, 27.5, 25.8, 25.2, 22.6, 18.1, 15.1, 14.1, 
10.5, −4.4, −4.42; HRMS (ESI TOF) Calcd. for C21H47NOSi 
[M + H+]: 358.3505. Found: 358.3428.
Synthesis of (±)-1-[(tert-Butyldimethylsilyl)oxy]- 
1-(3-chlorophenyl)propan-2-ol (60)
To a solution of acyloin 34 (170 mg, 0.57 mmol) in 
anhydrous methanol (10 mL), under argon atmosphere 
and at 0 oC was added NaBH4 (108.3 mg, 2.85 mmol). 
The resulting mixture was stirred for 10 min, after that 
1 mL of water was added and the solvent was removed 
under reduced pressure. The residue was diluted with ethyl 
acetate (15 mL) and the organic phase was washed with 
brine (5 mL), dried over anhydrous Na2SO4 and the solvent 
was removed under vacuum to provide the alcohol 60, in 
almost quantitative yield. Thus, it was used to the next step 
without purification. Colorless oil; IR (film) nmax/cm-1: 3448, 
2949, 2933, 2851, 1462, 1254, 1070, 833, 775; 1H NMR 
(250 MHz, CDCl3): d (mixture of diastereomers) 7.12-7.35 
(m, 6H), 4.52 (d, J 4.7 Hz, Ha
’), 4.28 (d, J 6.5 Hz, Ha), 3.80 
(q, J 4.7 Hz, Hb
’), 3.70 (q, J 6.5 Hz, Hb), 2.36 (s, 1H), 1.06 
(d3H,, J 6.5 Hz, CH3
’), 1.00, (d, 3H, J 6.5 Hz, CH3), 0.89 
(s, 9H), 0.05 (s, 3H), −0.12 (s, 3H); 13C NMR (75.4 MHz, 
CDCl3): d (diastereomeric mixture) 143.7, 143.3, 134.1, 
133.9, 129.5, 129.3, 127.9, 127.7, 127.1, 125.2, 125.1, 80.0, 
78.2, 72.4, 71.9, 25.8, 18.2, 18.1, 17.9, 17.6, −4.9; HRMS 
(ESI TOF) Calcd. for C15H25ClO2Si [M + H
+]: 301.1391. 
Found: 301.1577.
Synthesis of (±)-1-(3-chlorophenyl)propane-1,2-diol (61)
To a solution of alcohol (±)-60 (100 mg, 0.34 mmol) in 
THF (6 mL) at 0o C was added a solution of TBAF (0.41 mL, 
1 mol L-1 in toluene). The mixture was stirred for 5 min and 
was warmed to room temperature. After 2 h, a mixture of 
water (5 mL) and ethyl acetate (15 mL) was added to the 
reaction medium. The organic phase was separated, washed 
with brine (5 mL), dried over anhydrous Na2SO4 and the 
solvent was removed under vacuum. The residue was 
filtered through silica gel (solvent: ethyl acetate) to provide 
the diol (±)-61, in 97% yield. Colorless oil; IR (film) 
nmax/cm-1: 3395, 2978, 2876, 1569, 1426, 1082, 1037, 
780, 694; 1H NMR (250 MHz, CDCl3): d (diastereomeric 
mixture) 7.16-7.39 (m, 6H), 4.67 (d, J 4.0 Hz, Ha
’), 4.33 (d, 
J 7.1 Hz, Ha), 3.92-4.07 (m, Hb
’), 3.81 (q, J 7.1 Hz, Hb), 2.62 
(s, 3H, OH), 1.00-1.13 (m, 5H, CH3); 
13C NMR (62.5 MHz, 
CDCl3): d (diastereomeric mixture) 143.1, 142.4, 134.4, 
129.7, 129.5, 128.2, 127.8, 127.0, 126.7, 125.1, 124.8, 78.6, 
77.2, 71.9, 71.0, 18.7, 16.9; HRMS (ESI TOF) Calcd. for 
C9H11O2Cl [M + Na
+]: 209.6252. Found: 209.6223.
Synthesis of (±)-1-(3-chlorophenyl)-2-hydroxypropan- 
1-one (59)
To a solution of diol (±)-61 (70 mg, 0.38 mmol) in 
DMSO (1 mL) was slowly added 45% IBX (236.4 mg, 
0.38 mmol) at room temperature. Caution: addition 
time 15 h, faster addition will give a diketone product. 
The mixture was stirred for 30 h. After that, the reaction 
medium was diluted with water (5 mL) and ethyl acetate 
(15 mL). The organic phase was separated, washed with 
brine (5 mL), dried over anhydrous Na2SO4 and the solvent 
was removed under vacuum. The residue was purified by 
silica gel column chromatography (solvent: hexanes:ethyl 
acetate, up to 60:40) to provide the acyloin (±)-59, in 85% 
yield. Yellowish oil; IR (film) nmax/cm-1: 3436, 2982, 2921, 
2843, 1687, 1569, 1262, 1123, 1070, 1033, 739; 1H NMR 
(250 MHz, CDCl3): d 7.91 (s, 1H), 7.77-7.82 (m, 1H), 
7.57-7.62 (m, 1H), 7.46 (t, 1H, J 7.9 Hz), 5.12 (q, 1H, 
J 7.0 Hz, CH), 1.45 (d, 3H, J 7.0 Hz, CH3); 
13C NMR 
(75.4 MHz, CDCl3): d 201.3, 135.3, 134.9, 133.9, 130.2, 
128.7, 126.6, 77.2, 69.5, 22.1; HRMS (ESI TOF) Calcd. for 
C9H9O2Cl [M + Na
+]: 207.6093. Found: 207.6075.
Synthesis of (±)-2-(tert-butylamino)-1-(3-chlorophenyl)
propan-1-one (bupropion) (1)
To a solution of acyloin (±)-59 (30 mg, 0.16 mmol) in 
3 mL of anhydrous CH2Cl2, at −78 ˚C, was added triflic 
anhydride (50 mg, 0.177 mmol, 29.81 mL) and 2,6-lutidine 
(26 mg, 0.24 mmol, 28.26 mL). The resulting mixture 
was cooled to −40 oC and stirred for 30 min. After that, 
the organic phase was washed with brine (5 mL), dried 
over anhydrous Na2SO4 and the solvent was removed 
under vacuum. The residue was immediately dissolved 
in dry CH2Cl2 and the solution was cooled to −40 
oC. 
Then tert-butylamine (29.6 mg, 0.41 mmol, 42.5 mL) was 
added. The mixture was stirred for 2 h at −40 oC, warmed 
to 0 oC and kept at this final temperature for 12 h. After, 
the reaction medium was diluted with dichloromethane 
(10 mL). The organic phase was separated, washed 
with sodium bicarbonate (5 mL), water (5 mL), brine 
(5 mL), dried over anhydrous Na2SO4 and the solvent 
was removed under reduced pressure. The residue 
was purified through silica gel (solvent: hexanes:ethyl 
acetate, up to 60:40) to provide (±)-1 as a white solid, 
in 75% yield; mp 233-234 °C (as hydrochloride;41 
233-234 °C); 1H NMR (250 MHz, CDCl3): d 7.83-7.90 
(m, 1H), 8.03-8.11 (m, 1H), 7.97-7.99 (m, 1H), 6.11 
(q, 1H, J 7.0 Hz, CH), 4.65 (s, 1H, NH), 1.67 (t, 3H, 
J 7.0 Hz, CH3), 1.44 (s, 9H); 
13C NMR (62.5 MHz, CDCl3): 
d 195.7, 136.0, 135.2, 133.5, 130.1, 128.6, 126.5, 71.9, 
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58.1, 30.3, 17.0; HRMS (ESI TOF) Calcd. for C13H18OClN 
[M + Na+]: 262.7309. Found: 262.7299.
S y n t h e s i s  o f  ( ± ) - 1 , 2 - a n t i - b e n z y l ( { 3 - [ ( t e r t -
butyldimethylsilyl)oxy]octadecan-2-yl})amine (62)
To a stirred mixture of acyloin (±)-42 (0.2 g, 0.502 mmol) 
and molecular sieves (4 Å) in anhydrous dichloromethane 
(3 mL), under an argon atmosphere, was added distilled 
benzylamine (0.268 g, 0.27 mL, 2.51 mmol). The resulting 
mixture was kept at 40 °C for 7 h. Then, the reaction was 
cooled to 0 °C and NaBH3CN (0.038 g, 0.6 mmol) was 
added in three small portions at 40 min. intervals. The 
reaction was warmed to room temperature and stirred for 
12 h. The solvent was removed under reduced pressure and 
the residue was dissolved with ethyl acetate. The organic 
phase was filtered, washed with distilled water (3 × 10 mL), 
brine (15 mL), dried over anhydrous sodium sulfate and 
evaporated. The crude residue was purified by silica gel 
column chromatography (ethyl acetate:hexane, 25:75) 
to provide anti aminoalcohol 62 (0.19 g), as a viscous 
colorless oil, in 70% yield; IR (film) nmax/cm-1: 2925, 
2854, 1463, 1254, 1030; 1H NMR (250 MHz, CDCl3): 
d 7.22-7.32 (m, 5H), 3.89 (d, 1H, J 13.2 Hz), 3.67 (d, 1H, 
J 13.2 Hz), 3.54 (q, 1H, J 4.6 Hz), 2.69 (q, 1H, J 6.0 Hz), 
1.32-1.48 (m, 2H), 1.17-1.35 (m, 26H), 1.02 (d, 3H, 
J 6.5 Hz), 0.82-0.92 (m, 12H), 0.04 (s, 3H), −0.02 (s, 3H); 
13C NMR (62.5 MHz, CDCl3): d 140.6, 128.3, 128.14, 
128.1, 126.8, 75.4, 56.3, 51.5, 32.1, 31.9, 29.8, 29.7, 
29.65, 29.6, 29.4, 26.1, 25.9, 22.7, 18.1, 15.2, 14.1, −4.3, 





To a stirred solution of aminoalcohol (±)-62 (0.025 g, 
0.05 mmol) in a mixture of dichloromethane (1.5 mL) and 
acetic acid (1.0 mL) was added 10% Pd/C (0.006 g). The 
resulting suspension was purged twice with hydrogen gas 
and kept under a hydrogen atmosphere. Then, the reaction 
was warmed at 50 °C and stirred for 20 h under hydrogen 
atmosphere. After that time, the reaction mixture was 
diluted with dichloromethane (10 mL) and the organic 
phase was washed with a saturated solution of NaHCO3 
(8 mL), dried over anhydrous sodium sulfate and evaporated. 
The crude residue was filtered over a plug of silica gel 
(dichloromethane:methanol, 97:3, as eluent) to provide 
silylated aminoalcohol (±)-63 (0.018 g), as a viscous 
colorless oil, in 90% yield; IR (film) nmax/cm-1: 3409, 2926, 
2855, 1682, 1465, 1255, 1084; 1H NMR (250 MHz, CDCl3): 
d 3.45-3.60 (m, 1H), 2.85-2.99 (m, 1H), 1.10-1.45 (m, 28H), 
1.01 (d, 3H, J 6.6 Hz), 0.80-0.91 (m, 12H), 0.0-0.10 (m, 6H); 
13C NMR (62.5 MHz, CDCl3): d 77.2, 56.3, 50.8, 31.9, 31.6, 
29.8, 29.7, 29.6, 29.3, 25.9, 25.7, 22.7, 18.1, 17.9, 14.1, −4.3, 
−4.4; HRMS (ESI TOF) Calcd. for C24H53NOSi [M + H]
+: 
400.3964. Found: 400.3960.
Synthesis of (±)-1,2-anti-2-aminooctadecan-3-ol 
(spisulosine) (2)
To a stirred solution of aminoalcohol (±)-63 (0.01 g, 
0.025 mmol) in a mixture of dichloromethane (0.5 mL) and 
methanol (0.5 mL) was added a solution of concentrated 
hydrochloric acid (0.1 mL). The resulting mixture was 
warmed to 50 °C and stirred for 20 h. Then, the solvents 
were removed under reduced pressure and the residue 
was dissolved in dichloromethane (5 mL). To the stirred 
organic phase was added a saturated sodium bicarbonate 
solution (5 mL) and the resulting mixture was vigorously 
stirred for 30 min. The organic phase was separated, dried 
over anhydrous sodium sulfate and removed under reduced 
pressure. The crude residue was filtered over a plug of 
Florisil® to provide (±)-spisulosine (1, 7 mg), as a white 
solid, in 98% yield; mp 58-59 °C; IR (film) nmax/cm-1: 
3348, 3297, 2955, 2919, 2851, 1607, 1471; 1H NMR (250 MHz, 
CDCl3): d 3.39-3.47 (m, 1H), 2.88-3.06 (m, 1H), 1.64-1.88 (bs, 
3H), 1.20-1.40 (m, 28H), 1.01 (d, 3H, J 6.5 Hz), 0.88 (t, 3H, 
J 7.0 Hz); 13C NMR (62.5 MHz, CDCl3): d 74.7, 50.3, 32.4, 
31.9, 29.8, 29.7, 29.6, 29.3, 26.2, 22.7, 16.8, 14.1; HRMS 




All the spectra of the synthesized compounds in this 
paper are available as supplementary file and are free of 
charge at http/jbcs.sbq.org.br as pdf file.
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General
The 1H and 13C spectra were recorded on Bruker at 250 MHz and 62.5 MHz respectively. The 1H and 13C spectra were 
also recorded on Inova instrument at 500 MHz and 125 MHz, respectively. The high resolution mass spectra were recorded 
using a Q-TOF Micromass equipment (Waters, UK).
Figure S1. 1H NMR (CDCl3, 500 MHz) of MBH adduct 3.
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Figure S2. 13C NMR (CDCl3, 125 MHz) of MBH adduct 3.
Figure S3. 1H NMR (CDCl3, 250 MHz) of MBH adduct 4.
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Figure S4. 13C NMR (CDCl3, 62.5 MHz) of MBH adduct 4.
Figure S5. 1H NMR (CDCl3, 250 MHz) of MBH adduct 5.
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Figure S6. 13C NMR (CDCl3, 62.5 MHz) of MBH adduct 5.
Figure S7. 1H NMR (CDCl3, 250 MHz) of MBH adduct 6.
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Figure S8. 13C NMR (CDCl3, 62.5 MHz) of MBH adduct 6.
Figure S9. 1H RMN (CDCl3, 250 MHz) of MBH adduct 7.
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Figure S10. 13C NMR (CDCl3, 62.5 MHz) of MBH adduct 7.
Figure S11. 1H NMR (CDCl3, 250 MHz) of MBH adduct 8.
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Figure S12. 13C NMR (CDCl3, 62.5 MHz) of MBH adduct 8.
Figure S13. 1H NMR (CDCl3, 250 MHz) of MBH adduct 9.
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Figure S14. 13C NMR (CDCl3, 62.5 MHz) of MBH adduct 9.
Figure S15. 1H NMR (CDCl3, 250 MHz) of MBH adduct 10.
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Figure S16. 13C NMR (CDCl3, 62.5 MHz) of MBH adduct 10.
Figure S17. 1H NMR (CDCl3, 250 MHz) of MBH adduct 11.
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Figure S18. 13C NMR (CDCl3, 125 MHz) of MBH adduct 11.
Figure S19. 1H NMR (CDCl3, 250 MHz) of MBH adduct 12.
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Figure S20. 13C NMR (CDCl3, 125 MHz) of MBH adduct 12.
Figure S21. 1H NMR (CDCl3, 250 MHz) of silylated MBH adduct 13.
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Figure S22. 13C RMN (CDCl3, 62.5 MHz) of silylated MBH adduct 13.
Figure S23. 1H NMR (CDCl3, 250 MHz) of silylated MBH adduct 14.
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Figure S24. 13C NMR (CDCl3, 62.5 MHz) of silylated MBH adduct 14.
Figure S25. 1H NMR (CDCl3, 250 MHz) of silylated MBH adduct 15.
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Figure S26. 13C NMR (CDCl3, 62.5 MHz) of silylated MBH adduct 15.
Figure S27.1H NMR (CDCl3, 250 MHz) of silylated MBH adduct 16.
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Figure S28. 13C NMR (CDCl3, 125 MHz) of silylated MBH adduct 16. 
Figure S29. 1H NMR (CDCl3, 250 MHz) of silylated MBH adduct 17.
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Figure S30. 13C NMR (CDCl3, 62.5 MHz) of silylated MBH adduct 17.
Figure S31. 1H NMR (CDCl3, 250 MHz) of silylated MBH adduct 18.
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Figure S32. 13C NMR (CDCl3, 62.5 MHz) of silylated MBH adduct 18.
Figure S33. 1H NMR (CDCl3, 250 MHz) of silylated MBH adduct 19.
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Figure S34. 13C NMR (CDCl3, 62.5 MHz) of silylated MBH adduct 19.
Figure S35. 1H NMR (CDCl3, 250 MHz) of silylated MBH adduct 20.
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Figure S36. 13C NMR (CDCl3, 62.5 MHz) of silylated MBH adduct 20.
Figure S37. 1H NMR (CDCl3, 250 MHz) of silylated MBH adduct 21.
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Figure S38. 13C NMR (CDCl3, 62.5 MHz) of silylated MBH adduct 21.
Figure S39. 1H NMR (CDCl3, 250 MHz) of silylated MBH adduct 22.
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Figure S40. 13C NMR (CDCl3, 62.5 MHz) of silylated MBH adduct 22.
Figure S41. 1H NMR (CDCl3, 250 MHz) of silylated acid 23.
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Figure S42. 13C NMR (CDCl3, 62.5 MHz) of silylated acid 23.
Figure S43. 1H NMR (CDCl3, 250 MHz) of silylated acid 24.
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Figure S44. 13C NMR (CDCl3, 62.5 MHz) of silylated acid 24.
Figure S45. 1H NMR (CDCl3, 250 MHz) of silylated acid 25.
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Figure S46. 13C NMR (CDCl3, 62.5 MHz) of silylated acid 25.
Figure S47. 1H NMR (CDCl3, 250 MHz) of silylated acid 26.
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Figure S48. 13C NMR (CDCl3, 125 MHz) of silylated acid 26.
Figure S49. 1H NMR (CDCl3, 250 MHz) of silylated acid 27.
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Figure S50.13C NMR (CDCl3, 62.5 MHz) of silylated acid 27.
Figure S51. 1H NMR (CDCl3, 250 MHz) of silylated acid 28.
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Figure S52. 13C NMR (CDCl3, 62.5 MHz) of silyated acid 28.
Figure S53. 1H NMR (CDCl3, 250 MHz) of silylated acid 29.
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Figure S54. 13C NMR (CDCl3, 62.5 MHz) of silylated acid 29.
Figure S55. 1H NMR (CDCl3, 250 MHz) of silylated acid 30.
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Figure S56. 13C NMR (CDCl3, 62.5 MHz) of silylated acid 30.
Figure S57. 1H NMR (CDCl3, 250 MHz) of silylated acid 31.
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Figure S58. 13C NMR (CDCl3, 62.5 MHz) of silylated acid 31.
Figure S59. 1H NMR (CDCl3, 250 MHz) of silylated acid 32.
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Figure S60. 13C NMR (CDCl3, 62.5 MHz) of silylated acid 32.
Figure S61. 1H NMR (CDCl3, 250 MHz) of acyloin 33.
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Figure S62. 13C NMR (CDCl3, 62.5 MHz) of acyloin 33.
Figure S63. 1H NMR (CDCl3, 250 MHz) of acyloin 34.
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Figure S64. 13C NMR (CDCl3, 62.5 MHz) of acyloin 34.
Figure S65. 1H NMR (CDCl3, 250 MHz) of acyloin 35.
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Figure S66. 13C NMR (CDCl3, 125 MHz) of acyloin 35.
Figure S67. 1H NMR (CDCl3, 250 MHz) of acyloin 36.
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Figure S68. 13C NMR (CDCl3, 62.5 MHz) of acyloin 36.
Figure S69. 1H NMR (CDCl3, 250 MHz) of acyloin 37.
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Figure S70. 13C NMR (CDCl3, 62.5 MHz) of acyloin 37.
Figure S71. 1H NMR (CDCl3, 250 MHz) of acyloin 38.
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Figure S72. 13C NMR (CDCl3, 62.5 MHz) of acyloin 38.
Figure S73. 1H NMR (CDCl3, 250 MHz) of acyloin 39.
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Figure S74. 13C NMR (CDCl3, 62.5 MHz) of acyloin 39.
Figure S75. 1H NMR (CDCl3, 250 MHz) of acyloin 40.
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Figure S76. 13C NMR (CDCl3, 62.5 MHz) of acyloin 40.
Figure S77. 1H NMR (CDCl3, 250 MHz) of acyloin 41.
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Figure S78.13C NMR (CDCl3, 62.5 MHz) of acyloin 41.
Figure S79. 1H NMR (CDCl3, 250 MHz) of acyloin 42.
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Figure S80. 13C NMR (CDCl3, 62.5 MHz) of acyloin 41.
Figure S81. 1H NMR (CDCl3, 250 MHz) of vicinal aminoalcohol 43.
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Figure S82. 13C NMR (CDCl3, 62.5 MHz) of vicinal aminoalcohol 43.
Figure S83. DEPT 135 (CDCl3, 62.5 MHz) of of vicinal aminoalcohol 43.
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Figure S84. 1H NMR (CDCl3, 250 MHz) of vicinal aminoalcohol 44.
Figure S85. 13C NMR (CDCl3, 62.5 MHz) of vicinal aminoalcohol 44.
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Figure S86. DEPT 135 (CDCl3, 62.5 MHz) of vicinal aminoalcohol 44.
Figure S87.1H NMR (CDCl3, 250 MHz) of vicinal aminoalcohol 45.
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Figure S88. 13C NMR (CDCl3, 62.5 MHz) of vicinal aminoalcohol 45.
Figure S89. DEPT 135 (CDCl3, 62.5 MHz) of vicinal aminoalcohol 45.
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Figure S90. 1H NMR (CDCl3, 250 MHz) of vicinal aminoalcohol 46.
Figure S91. 13C NMR (CDCl3, 62.5 MHz) of vicinal aminoalcohol 46.
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Figure S92. 1H NMR (CDCl3, 250 MHz) of vicinal aminoalcohol 47.
Figure S93. 13C NMR (CDCl3, 62.5 MHz) of vicinal aminoalcohol 47.
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Figure S94. DEPT 135 (CDCl3, 62.5 MHz) of vicinal aminoalcohol 47.
Figure S95. 1H NMR (CDCl3, 250 MHz) of vicinal aminoalcohol 48.
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Figure S96. 13C NMR (CDCl3, 62.5 MHz) of vicinal aminoalcohol 48.
Figure S97. DEPT 135 (CDCl3, 62.5 MHz) of vicinal aminoalcohol 48.
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Figure S98. 1H NMR (CDCl3, 250 MHz) of vicinal aminoalchol 49.
Figure S99. 13C NMR (CDCl3, 62.5 MHz) of vicinal aminoalcohol 49.
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Figure S100. DEPT 135 (CDCl3, 62.5 MHz) of vicinal aminoalcohol 49.
Figure S101. 1H NMR (CDCl3, 250 MHz) of vicinal aminoalcohol 50.
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Figure S102. 13C NMR (CDCl3, 62.5 MHz) of vicinal aminoalcohol 50.
Figure S103. DEPT 135 (CDCl3, 62.5 MHz) of vicina aminoalcohol 50.
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Figure S104. 1H NMR (CDCl3, 250 MHz) of vicinal aminoalcohol 51.
Figure S105. 13C NMR (CDCl3, 62.5 MHz) of vicinal aminoalcohol 51.
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Figure S106. 1H NMR (CDCl3, 250 MHz) of vicinal aminoalcohol 52.
Figure S107. 13C NMR (CDCl3, 62.5 MHz) of vicinal aminoalcohol 52.
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Figure S108. 1H NMR (CDCl3, 250 MHz) of vicinal aminoalcohol 53.
Figure S109. 13C NMR (CDCl3, 62.5 MHz) of vicinal aminoalcohol 53.
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Figure S110. DEPT 135 (CDCl3, 62.5 MHz) of vicinal aminoalcohol 53.
Figure S111. 1H NMR (CDCl3, 250 MHz) of vicinal aminoalcohol 54.
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Figure S112. 13C NMR (CDCl3, 62.5 MHz) of vicinal aminoalcohol 54.
Figure S113. 1H NMR (CDCl3, 250 MHz) of monosilylated diol 60.
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Figure S114. 13C NMR (CDCl3, 75.4 MHz) of monosilylated diol 60.
Figure S115. 1H NMR (CDCl3, 250 MHz) of diol 61.
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Figure S116. 1H NMR (CDCl3 + 2 drops of D2O, 250 MHz) of diol 61.
Figure S117. 13C NMR (CDCl3, 62.5 MHz) of diol 61.
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Figure S118.1H NMR (CDCl3, 250 MHz) of acyloin 59.
Figure S119. 13C NMR (CDCl3, 75.4 MHz) of acyloin 59.
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Figure S120. 1H NMR (CDCl3, 250 MHz) of bupropion (1).
Figure S121. 13C NMR (CDCl3, 62.5 MHz) of bupropion (1).
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Figure S122. 1H NMR (CDCl3, 250 MHz) of hexadecanal.
Figure S123. 13C NMR (CDCl3, 62.5 MHz) of hexadecanal.
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Figure S124. 1H NMR (CDCl3, 250 MHz) of vicinal aminoalcohol 62.
Figure S125. 13C NMR (CDCl3, 62.5 MHz) of vicinal aminoalcohol 62.
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Figure S126. 1H NMR (CDCl3, 250 MHz) of silylated aminoalcohol 63.
Figure S127. 13C NMR (CDCl3, 62.5 MHz) of silylated aminoalcohol 63.
Amarante et al. S65Vol. 22, No. 8, 2011
Figure S128. 1H NMR (CDCl3, 250 MHz) of spisulosine (2).
Figure S129. 13C NMR (CDCl3, 62.5 MHz) of spisulosine (2).
